{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:10:22Z","timestamp":1790053822205,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40268-020-00313-4","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T21:06:36Z","timestamp":1592514396000},"page":"249-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of K\u00e9ni\u00e9roba, a Malaria Endemic Village in Mali"],"prefix":"10.1007","volume":"20","author":[{"given":"Karim","family":"Traor\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seidina A. S.","family":"Diakit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekou","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drissa S.","family":"Konat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djeneba","family":"Dabitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Sanogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modibo","family":"Sangar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souleymane","family":"Dama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bourama","family":"Keita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mory","family":"Doumbouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merepen A.","family":"Guindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seydou","family":"Doumbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamadou","family":"Diakit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"313_CR1","doi-asserted-by":"crossref","DOI":"10.30875\/1cee73f9-en","volume-title":"World malaria report 2015","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. World malaria report 2015. Geneva: World Health Organization; 2015."},{"issue":"5","key":"313_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMp1403340","volume":"371","author":"RM Packard","year":"2014","unstructured":"Packard RM. The origins of antimalarial-drug resistance. N Engl J Med. 2014;371(5):397\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"313_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(02)00239-6","volume":"2","author":"C Wongsrichanalai","year":"2002","unstructured":"Wongsrichanalai C, et al. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2(4):209\u201318.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"313_CR4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/0035-9203(85)90108-7","volume":"79","author":"HC Spencer","year":"1985","unstructured":"Spencer HC. Drug-resistant malaria: changing patterns mean difficult decisions. Trans R Soc Trop Med Hyg. 1985;79(6):748\u201358.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"313_CR5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0163-7258(91)90074-V","volume":"50","author":"WH Wernsdorfer","year":"1991","unstructured":"Wernsdorfer WH, Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther. 1991;50(1):95\u2013121.","journal-title":"Pharmacol Ther"},{"key":"313_CR6","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2011."},{"issue":"9830","key":"313_CR7","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0140-6736(12)60484-X","volume":"379","author":"AP Phyo","year":"2012","unstructured":"Phyo AP, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379(9830):1960\u20136.","journal-title":"Lancet"},{"issue":"11","key":"313_CR8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1473-3099(12)70181-0","volume":"12","author":"C Amaratunga","year":"2012","unstructured":"Amaratunga C, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12(11):851\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"7481","key":"313_CR9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50\u20135.","journal-title":"Nature"},{"issue":"5","key":"313_CR10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4269\/ajtmh.16-0483","volume":"95","author":"C Tacoli","year":"2016","unstructured":"Tacoli C, et al. Artemisinin resistance-associated K13 polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010\u20132015. Am J Trop Med Hyg. 2016;95(5):1090\u20133.","journal-title":"Am J Trop Med Hyg"},{"key":"313_CR11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijpddr.2019.04.002","volume":"10","author":"J Zhang","year":"2019","unstructured":"Zhang J, et al. In vitro susceptibility of Plasmodium falciparum isolates from the China\u2013Myanmar border area to artemisinins and correlation with K13 mutations. Int J Parasitol Drugs Drug Resist. 2019;10:20\u20137.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"313_CR12","unstructured":"OMS. Rapport mondial sur l'efficacit\u00e9 des m\u00e9dicaments antipaludiques et la pharmacor\u00e9sistance: 2000\u20132010. Gen\u00e8ve, S.O.m.d.l.s., rapport mondial sur l'efficacit\u00e9 des m\u00e9dicaments antipaludiques et la pharmacor\u00e9sistance: 2000\u20132010. Gen\u00e8ve: Organisation mondiale de la sant\u00e9; 2011."},{"issue":"4809","key":"313_CR13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1126\/science.3299700","volume":"236","author":"D Walliker","year":"1987","unstructured":"Walliker D, et al. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science. 1987;236(4809):661\u20136.","journal-title":"Science"},{"issue":"6272","key":"313_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/345253a0","volume":"345","author":"TE Wellems","year":"1990","unstructured":"Wellems TE, et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature. 1990;345(6272):253\u20135.","journal-title":"Nature"},{"issue":"5","key":"313_CR15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1128\/AAC.48.5.1803-1806.2004","volume":"48","author":"M Smilkstein","year":"2004","unstructured":"Smilkstein M, et al. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother. 2004;48(5):1803\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"313_CR16","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/AAC.01607-06","volume":"51","author":"JD Johnson","year":"2007","unstructured":"Johnson JD, et al. Assessment and continued validation of the malaria SYBR Green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother. 2007;51(6):1926\u201333.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8706","key":"313_CR17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0140-6736(90)91578-X","volume":"336","author":"P Brasseur","year":"1990","unstructured":"Brasseur P, et al. Emergence of mefloquine-resistant malaria in Africa without drug pressure. Lancet. 1990;336(8706):59.","journal-title":"Lancet"},{"key":"313_CR18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1475-2875-10-268","volume":"10","author":"B Pradines","year":"2011","unstructured":"Pradines B, et al. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Malar J. 2011;10:268.","journal-title":"Malar J"},{"issue":"2","key":"313_CR19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1590\/S0074-02761997000200019","volume":"92","author":"JM Reynes","year":"1997","unstructured":"Reynes JM, et al. In vitro responses of Plasmodium falciparum isolates to five antimalaria drugs in French Guiana during 1994 and 1995. Mem Inst Oswaldo Cruz. 1997;92(2):251\u20132.","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"313_CR20","first-page":"88","volume":"81","author":"JP Dedet","year":"1988","unstructured":"Dedet JP, et al. In vitro activity of various antimalarials (chloroquine, amodiaquine, quinine and mefloquine) against 32 isolates of Plasmodium falciparum in French Guiana. Bull Soc Pathol Exot Filiales. 1988;81(1):88\u201393.","journal-title":"Bull Soc Pathol Exot Filiales"},{"issue":"5","key":"313_CR21","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4269\/ajtmh.2010.10-0339","volume":"83","author":"M Mungthin","year":"2010","unstructured":"Mungthin M, et al. Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. Am J Trop Med Hyg. 2010;83(5):1005\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"313_CR22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/1475-2875-10-310","volume":"10","author":"B Fall","year":"2011","unstructured":"Fall B, et al. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J. 2011;10:310.","journal-title":"Malar J"},{"key":"313_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12936-015-0586-6","volume":"14","author":"A Pascual","year":"2015","unstructured":"Pascual A, et al. Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Malar J. 2015;14:49.","journal-title":"Malar J"},{"issue":"4","key":"313_CR24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1128\/AAC.01313-06","volume":"51","author":"DJ Bacon","year":"2007","unstructured":"Bacon DJ, et al. Comparison of a SYBR Green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother. 2007;51(4):1172\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"313_CR25","first-page":"136","volume":"39","author":"EA Afari","year":"1993","unstructured":"Afari EA, et al. In vitro responses of P. falciparum parasites to chloroquine, amodiaquine and quinine in two ecological zones in Ghana. Cent Afr J Med. 1993;39(7):136\u201340.","journal-title":"Cent Afr J Med."},{"issue":"1","key":"313_CR26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cmpb.2010.08.003","volume":"104","author":"H Le Nagard","year":"2011","unstructured":"Le Nagard H, et al. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Progr Biomed. 2011;104(1):10\u20138.","journal-title":"Comput Methods Progr Biomed"},{"issue":"10","key":"313_CR27","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1128\/AAC.00367-06","volume":"50","author":"H Kaddouri","year":"2006","unstructured":"Kaddouri H, et al. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother. 2006;50(10):3343\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"313_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-10-187","volume":"10","author":"B Kwansa-Bentum","year":"2011","unstructured":"Kwansa-Bentum B, et al. Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro. Malar J. 2011;10:187.","journal-title":"Malar J"},{"issue":"1","key":"313_CR29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12936-017-1773-4","volume":"16","author":"S Diawara","year":"2017","unstructured":"Diawara S, et al. Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015. Malar J. 2017;16(1):118.","journal-title":"Malar J"},{"issue":"1","key":"313_CR30","first-page":"43","volume":"18","author":"AO Tour\u00e9","year":"2008","unstructured":"Tour\u00e9 AO, et al. In vitro susceptibility of P. falciparum isolates from Abidjan (Cote d'Ivoire) to quinine, artesunate and chloroquine. Sante. 2008;18(1):43\u20137.","journal-title":"Sante."},{"issue":"7","key":"313_CR31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijpara.2007.12.002","volume":"38","author":"H Kaddouri","year":"2008","unstructured":"Kaddouri H, et al. Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol. 2008;38(7):791\u20138.","journal-title":"Int J Parasitol"},{"issue":"12","key":"313_CR32","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1086\/375419","volume":"187","author":"JG Kublin","year":"2003","unstructured":"Kublin JG, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187(12):1870\u20135.","journal-title":"J Infect Dis"},{"issue":"19","key":"313_CR33","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa062032","volume":"355","author":"MK Laufer","year":"2006","unstructured":"Laufer MK, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355(19):1959\u201366.","journal-title":"N Engl J Med"},{"key":"313_CR34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1475-2875-8-106","volume":"8","author":"L Mwai","year":"2009","unstructured":"Mwai L, et al. Chloroquine resistance before and after its withdrawal in Kenya. Malar J. 2009;8:106.","journal-title":"Malar J"},{"key":"313_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1475-2875-12-35","volume":"12","author":"M Gharbi","year":"2013","unstructured":"Gharbi M, et al. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000\u20132011. Malar J. 2013;12:35.","journal-title":"Malar J"},{"issue":"1","key":"313_CR36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13071-017-2298-y","volume":"10","author":"F Lu","year":"2017","unstructured":"Lu F, et al. Return of chloroquine sensitivity to Africa? Surveillance of African Plasmodium falciparum chloroquine resistance through malaria imported to China. Parasit Vectors. 2017;10(1):355.","journal-title":"Parasit Vectors"},{"issue":"4","key":"313_CR37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4103\/ijmm.IJMM_17_160","volume":"35","author":"S Sharma","year":"2017","unstructured":"Sharma S, et al. Correlation of in vitro sensitivity of chloroquine and other antimalarials with the partner drug resistance to Plasmodium falciparum malaria in selected sites of India. Indian J Med Microbiol. 2017;35(4):485\u201390.","journal-title":"Indian J Med Microbiol"},{"key":"313_CR38","volume-title":"WHO briefing on malaria treatment guidelines and artemisinin monotherapies","author":"World Health Organization","year":"2006","unstructured":"World Health Organization. WHO briefing on malaria treatment guidelines and artemisinin monotherapies. Geneva: World Health Organization; 2006."},{"issue":"1","key":"313_CR39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12936-017-1700-8","volume":"16","author":"S Dama","year":"2017","unstructured":"Dama S, et al. Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali. Malar J. 2017;16(1):59.","journal-title":"Malar J"},{"key":"313_CR40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1475-2875-12-107","volume":"12","author":"B Fall","year":"2013","unstructured":"Fall B, et al. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J. 2013;12:107.","journal-title":"Malar J"},{"issue":"2","key":"313_CR41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/AAC.43.2.418","volume":"43","author":"B Pradines","year":"1999","unstructured":"Pradines B, et al. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother. 1999;43(2):418\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"313_CR42","doi-asserted-by":"crossref","first-page":"e00374","DOI":"10.1128\/AAC.00374-18","volume":"62","author":"MG Robert","year":"2018","unstructured":"Robert MG, et al. Absence of a high level of duplication of the plasmepsin II gene in Africa. Antimicrob Agents Chemother. 2018;62(11):e00374\u2013e418.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"313_CR43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1128\/JCM.37.3.700-705.1999","volume":"37","author":"P Ringwald","year":"1999","unstructured":"Ringwald P, et al. In vitro culture and drug sensitivity assay of Plasmodium falciparum with nonserum substitute and acute-phase sera. J Clin Microbiol. 1999;37(3):700\u20135.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"313_CR44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/42.3.333","volume":"42","author":"B Pradines","year":"1998","unstructured":"Pradines B, et al. In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. J Antimicrob Chemother. 1998;42(3):333\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"313_CR45","first-page":"381","volume":"3","author":"JB Ouedraogo","year":"1998","unstructured":"Ouedraogo JB, et al. In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa). Trop Med Int Health. 1998;3(5):381\u20134.","journal-title":"Trop Med Int Health"},{"issue":"2","key":"313_CR46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4269\/ajtmh.1999.61.187","volume":"61","author":"P Ringwald","year":"1999","unstructured":"Ringwald P, Bickii J, Basco LK. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg. 1999;61(2):187\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"313_CR47","doi-asserted-by":"crossref","unstructured":"East African Network for Monitoring Antimalarial Treatment (EANMAT). Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience. Trop Med Int Health. 2001;6(11):891\u20138.","DOI":"10.1046\/j.1365-3156.2001.00799.x"},{"issue":"5","key":"313_CR48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4314\/eamj.v79i5.8860","volume":"79","author":"M Randrianarivelojosia","year":"2002","unstructured":"Randrianarivelojosia M, et al. In-vitro sensitivity of Plasmodium falciparum to chloroquine, halofantrine, mefloquine and quinine in Madagascar. East Afr Med J. 2002;79(5):237\u201341.","journal-title":"East Afr Med J"},{"issue":"2","key":"313_CR49","first-page":"111","volume":"10","author":"W Yavo","year":"2010","unstructured":"Yavo W, et al. In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Cote d'Ivoire). Afr Health Sci. 2010;10(2):111\u20136.","journal-title":"Afr Health Sci"},{"key":"313_CR50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/1475-2875-9-273","volume":"9","author":"K Na-Bangchang","year":"2010","unstructured":"Na-Bangchang K, et al. Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. Malar J. 2010;9:273.","journal-title":"Malar J"},{"issue":"19\u201320 Suppl. 3","key":"313_CR51","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00508-007-0872-6","volume":"119","author":"B Woitsch","year":"2007","unstructured":"Woitsch B, et al. Susceptibility to chloroquine, mefloquine and artemisinin of Plasmodium vivax in northwestern Thailand. Wien Klin Wochenschr. 2007;119(19\u201320 Suppl. 3):76\u201382.","journal-title":"Wien Klin Wochenschr."},{"issue":"11","key":"313_CR52","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1086\/657120","volume":"51","author":"H Noedl","year":"2010","unstructured":"Noedl H, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51(11):e82\u2013e8989.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"313_CR53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","volume":"15","author":"MD Spring","year":"2015","unstructured":"Spring MD, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15(6):683\u201391.","journal-title":"Lancet Infect Dis"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00313-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T23:13:33Z","timestamp":1623971613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00313-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00313-4","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"18 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study is supported by the University of Sciences, Techniques, and Technologies of Bamako (USTTB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Karim Traor\u00e9, Seidina A.S. Diakit\u00e9, Sekou Bah, Drissa S. Konat\u00e9, Djeneba Dabitao, Ibrahim Sanogo, Modibo Sangar\u00e9, Souleymane Dama, Bourama Keita, Mory Doumbouya, Merepen A. Guindo, Seydou Doumbia, and Mahamadou Diakit\u00e9 have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Faculty of Medicine and Pharmacy of the University of Sciences, Techniques, and Technologies of Bamako (USTTB), Mali.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants signed a written consent or assent (for children) form to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}